Aiolos Bio, a clinical-stage biopharmaceutical company dedicated to revolutionising the treatment landscape for respiratory disease, is to be acquired by GSK for up to US$1.4bn, including US$1bn upfront and up…
London: GSK to pay up to US$1.4bn for Aiolos Bio
…
…






